Venus Concept

Venus Concept Receives FDA 510(k) Clearance for Venus NOVA Multi-Application Aesthetic Platform

- Venus Concept has received FDA 510(k) clearance for Venus NOVA, a next-generation multi-application platform combining electrical muscle stimulation, radiofrequency, and electromagnetic fields for non-invasive body and skin treatments. - The platform integrates FlexMAX EMS technology capable of delivering up to 100,000 muscle contractions per session across 8 muscle groups, along with proprietary (MP)² technology combining Multi-Polar RF with Pulsed Electromagnetic Fields. - Venus NOVA is positioned to address the growing GLP-1 medication market, with the company expecting GLP-1 usage to reach over 32 million patients globally by 2030. - The device will be commercially available in the United States in December 2025, with global rollouts planned throughout 2026 and beyond.